Terns Pharmaceuticals (TERN) EBIAT (2020 - 2023)
Terns Pharmaceuticals (TERN) has disclosed EBIAT for 4 consecutive years, with $69.0 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, EBIAT rose 537.89% year-over-year to $69.0 million, compared with a TTM value of -$86000.0 through Dec 2023, up 99.86%, and an annual FY2024 reading of -$88.9 million, up 1.5% over the prior year.
- EBIAT was $69.0 million for Q4 2023 at Terns Pharmaceuticals, up from -$29.7 million in the prior quarter.
- Across five years, EBIAT topped out at $69.0 million in Q4 2023 and bottomed at -$29.7 million in Q3 2023.
- Average EBIAT over 4 years is -$9.4 million, with a median of -$13.6 million recorded in 2021.
- Peak annual rise in EBIAT hit 537.89% in 2023, while the deepest fall reached 76.63% in 2023.
- Year by year, EBIAT stood at -$10.4 million in 2020, then plummeted by 36.38% to -$14.2 million in 2021, then dropped by 10.67% to -$15.8 million in 2022, then skyrocketed by 537.89% to $69.0 million in 2023.
- Business Quant data shows EBIAT for TERN at $69.0 million in Q4 2023, -$29.7 million in Q3 2023, and -$17.9 million in Q2 2023.